News|Articles|November 11, 2024
Day 4 Recap: Elevate-Derm West 2024
Author(s)Emma Andrus, Associate Editor
Listen
0:00 / 0:00
Key Takeaways
- Dr. Ashfaq Marghoob emphasized dermoscopic features to differentiate benign from malignant lesions in various body locations.
- Dr. Jenny Murase highlighted the unsuitability of small molecule treatments, like JAK inhibitors, for pregnant women.
Catch up on coverage from the fourth and final day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.
Advertisement
To stay informed with the latest conference insights,
Ashfaq Marghoob, MD: Identifying Dermoscopic Patterns in Facial, Palmoplantar, Nail, and Mucosal Lesions
Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.
Navigating Skin Disease Treatment During Pregnancy
Murase noted small molecule treatments, like JAK inhibitors, remain unsafe for pregnant women.
Pediatric Dermatology Essentials: Lisa Swanson, MD, on Treating Young Patients with Confidence
Swanson shared practical tips from her Elevate-Derm West sessions, empowering clinicians with new strategies for pediatric skin care.
Jenny Murase, MD: Emerging Therapies Bring Hope to Patients with Persistent Itch
At Elevate-Derm West, Murase shared promising results in treating severe itch with emerging therapies, offering hope for patients with few options.
Desert Gems in Dermatology: Insights from Elevate-Derm West 2024
Discover top innovations, insights, and clinical pearls from Elevate-Derm in Scottsdale, where top insights for advanced practice providers took center stage.
To view all conference coverage from Elevate-Derm West 2024,
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
